[Transcatheter arterial embolization with SMANCS and epiADM for hepatocellular carcinoma].
We have attempted transcatheter arterial embolization (TAE) with SMANCS and epiADM for 40 patients with hepatocellular carcinoma and evaluated its therapeutic effects and side effects. There were 7 cases of stage I disease, 10 cases of stage II disease, 10 cases of stage III disease and 13 cases of stage IV disease. Patients underwent TAE superselectively following infusion of w/o emulsion of epiADM and SMANCS-lipiodol. No severe side effect was observed compared with conventional Lp-TAE except in one case with hepatic biloma after treatment. The overall response rate was 70%, and 54.5% in the patients with recurrent tumor after Lp-TAE. The serum AFP value decreased in 16 patients out of 20 patients. Hepatic resection was performed in 2 patients after treatment, and no viable tumor cell was recognized in the specimen. Our result suggested that TAE with SMANCS and epiADM will contribute to improved therapeutic efficacy for hepatocellular carcinoma.
Ihaya
T
T
Dept. of Radiology, Tottori Red Cross Hospital.
Ametani
M
M
Matsusue
E
E
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D004334:Drug Administration Schedule; D004621:Embolization, Therapeutic; D015251:Epirubicin / Q000008:administration & dosage*; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008299:Maleic Anhydrides / Q000008:administration & dosage*; D008875:Middle Aged; D011137:Polystyrenes / Q000008:administration & dosage*; D009353:Zinostatin / Q000008:administration & dosage / Q000031:analogs & derivatives*
D008299:Maleic Anhydrides; D011137:Polystyrenes; C035755:poly(maleic acid-styrene)neocarzinostatin; D015251:Epirubicin; D007459:Iodized Oil; D009353:Zinostatin